Pilotti S, Di Palma S, Alasio L, Bartoli C, Rilke F
Division of Pathology and Cytology, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.
Acta Cytol. 1993 Nov-Dec;37(6):853-66.
Two hundred eighty-five consecutive outpatients with enlarged superficial lymph node either clinically suspicious (152) or with a previous diagnosis of a malignant tumor (133) underwent fine needle aspiration (FNA) followed by excisional biopsy. Cytologic and/or cytologic-immunophenotypic diagnoses made on direct smears were compared with subsequent histologic findings. The comparison demonstrated (1) a high rate of conclusive cytologic diagnoses in the assessment of metastatic malignancies, with an overall accuracy rate of 99.1% and a typing accuracy rate of 96.5%; (2) a high rate of conclusive diagnoses in the assessment of high grade non-Hodgkin's lymphomas and Hodgkin's disease, with the exception of the lymphocytic predominance variant of the latter; and (3) significant limitations in the assessment of low grade non-Hodgkin's lymphomas because of the high rate of false-negative diagnoses in cases with a substantial nonmalignant cell component. This was particularly evident in follicular centroblastic-centrocytic lymphomas. Immunocytochemistry appeared to be of limited value in the distinction between centroblastic-centrocytic follicular lymphomas and reactive follicular hyperplasia. The results confirmed the diagnostic value of fine needle aspiration as the first step in the workup of patients with nodal enlargement suspicious for malignancy. In the area of low grade non-Hodgkin's lymphomas, morphologic and immunocytochemical methods need to be supplemented by molecular techniques in order to achieve conclusive diagnoses.
285例连续门诊患者,其浅表淋巴结肿大,临床上可疑(152例)或先前诊断为恶性肿瘤(133例),均接受了细针穿刺抽吸活检(FNA),随后进行切除活检。将直接涂片的细胞学和/或细胞免疫表型诊断与后续组织学结果进行比较。比较结果显示:(1)在转移性恶性肿瘤评估中,细胞学确诊率较高,总体准确率为99.1%,分型准确率为96.5%;(2)在高级别非霍奇金淋巴瘤和霍奇金病评估中,确诊率较高,但后者的淋巴细胞为主型变异型除外;(3)在低级别非霍奇金淋巴瘤评估中存在显著局限性,因为在具有大量非恶性细胞成分的病例中假阴性诊断率较高。这在滤泡中心母细胞-中心细胞淋巴瘤中尤为明显。免疫细胞化学在区分中心母细胞-中心细胞滤泡性淋巴瘤和反应性滤泡增生方面似乎价值有限。结果证实了细针穿刺抽吸活检作为对可疑恶性淋巴结肿大患者进行检查的第一步的诊断价值。在低级别非霍奇金淋巴瘤领域,形态学和免疫细胞化学方法需要通过分子技术进行补充,以实现确诊。